Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Sascha Gottlieb"'
Autor:
Sebastian Spindeldreher, Anette Karle, Evelyne Correia, Maxime Tenon, Sascha Gottlieb, Thomas Huber, Bernard Maillere, Frank Kolbinger
Publikováno v:
mAbs, Vol 12, Iss 1 (2020)
Secukinumab, a human monoclonal antibody that selectively neutralizes IL-17A, has consistently shown low anti-drug antibody responses in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis. Secukinumab has also shown lower in vit
Externí odkaz:
https://doaj.org/article/0f77ce827ea54bc9b697edd19df709eb
Autor:
Verena Rombach-Riegraf, Anette C Karle, Babette Wolf, Laetitia Sordé, Stephan Koepke, Sascha Gottlieb, Jennifer Krieg, Marie-Claude Djidja, Aida Baban, Sebastian Spindeldreher, Atanas V Koulov, Andrea Kiessling
Publikováno v:
PLoS ONE, Vol 9, Iss 1, p e86322 (2014)
Subvisible proteinaceous particles which are present in all therapeutic protein formulations are in the focus of intense discussions between health authorities, academics and biopharmaceutical companies in the context of concerns that such particles
Externí odkaz:
https://doaj.org/article/fa83ce637c2e4d06ac0092c6385922b6
Autor:
Anette C. Karle, Matthias B. Wrobel, Stephan Koepke, Michael Gutknecht, Sascha Gottlieb, Brigitte Christen, Tina Rubic-Schneider, Ingrid Pruimboom-Brees, Xavier Charles Leber, Meike Scharenberg, Benjamin Maciejewski, Oliver Turner, Chandra Saravanan, Francois Huet, Amanda Littlewood-Evans, Andreas Clemens, Cynthia L. Grosskreutz, Jeffrey D. Kearns, Pawan Mehan, Robert L. Schmouder, Vito Sasseville, Dominique Brees
Publikováno v:
Science Translational Medicine. 15
In October 2019, Novartis launched brolucizumab, a single-chain variable fragment molecule targeting vascular endothelial growth factor A, for the treatment of neovascular age-related macular degeneration. In 2020, rare cases of retinal vasculitis an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b253d859f72c25188df64a4808680e73
https://doi.org/10.1126/scitranslmed.abq5241
https://doi.org/10.1126/scitranslmed.abq5241
Autor:
Thomas Huber, Frank Kolbinger, Maxime Tenon, Evelyne Correia, Bernard Maillere, Sebastian Spindeldreher, Anette Karle, Sascha Gottlieb
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Secukinumab, a human monoclonal antibody that selectively neutralizes IL-17A, has consistently shown low anti-drug antibody responses in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis. Secukinumab has also shown lower in vit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fb91c766ab92347bf9d19c15152f4b1
http://europepmc.org/articles/PMC8648323
http://europepmc.org/articles/PMC8648323